Whereas a decreasing trend in PRO claims was reported for FDA approvals from 2006 to 2015 [ 7 , 10 ], it is unknown if a similar trend occurred at the EMA.
← all excerpts
Patient-reported outcome claims in European and United States orphan drug approvals.
1
—
—